Jefferson BuendÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8332237/publications.pdf

Version: 2024-02-01

94

all docs

59 527 10
papers citations h-index

94

docs citations

94 508
times ranked citing authors

839053

18

g-index

#	Article	IF	CITATIONS
1	Burden and typing of rotavirus group A in Latin America and the Caribbean: systematic review and metaâ€analysis. Reviews in Medical Virology, 2011, 21, 89-109.	3.9	73
2	IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. International Journal of Technology Assessment in Health Care, 2015, 31, 2-11.	0.2	34
3	Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2009, 26, 341-349.	0.6	29
4	Costs of Respiratory Syncytial Virus Hospitalizations in Colombia. PharmacoEconomics - Open, 2021, 5, 71-76.	0.9	25
5	Evaluaci \tilde{A}^3 n econ \tilde{A}^3 mica del trastuzumab como tratamiento adyuvante en c \tilde{A}_i ncer de mama HER2-positivo en Colombia. Biomedica, 2013, 33, 411-7.	0.3	24
6	Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 442-447.	1.0	23
7	Burden of paraquat poisoning in the department of Antioquia, Colombia. BMC Pharmacology & Samp; Toxicology, 2019, 20, 11.	1.0	15
8	Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. Journal of Asthma, 2022, 59, 2016-2023.	0.9	13
9	Costo-Efectividad de la ProteÃna C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnosticas para la Identificación de Infección Bacteriana Severa en Lactantes Febriles sin Foco. Value in Health Regional Issues, 2013, 2, 375-380.	0.5	12
10	Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. Therapeutic Drug Monitoring, 2018, 40, 401-410.	1.0	12
11	Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma. Cost Effectiveness and Resource Allocation, 2021, 19, 33.	0.6	12
12	Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. Pharmaceutics, 2020, 12, 898.	2.0	11
13	The costâ€utility of intravenous magnesium sulfate for treating asthma exacerbations in children. Pediatric Pulmonology, 2020, 55, 2610-2616.	1.0	11
14	Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 299-305.	0.7	10
15	Cost-utility of use of sputum eosinophil counts to guide management in children with asthma. Journal of Asthma, 2022, 59, 31-37.	0.9	9
16	Disability-adjusted life years for respiratory syncytial virus in children under 2 years. BMC Public Health, 2020, 20, 1679.	1.2	9
17	Cost of illness of RSV infection in a middle-income tropical country. Turkish Journal of Pediatrics, 2021, 63, 673-682.	0.3	9
18	Costâ€utility of tiotropium for children with severe asthma in patients aged 1–5 years. Pediatric Allergy and Immunology, 2021, 32, 1866-1868.	1.1	9

#	Article	IF	CITATIONS
19	The cost-utility of early use of high-flow nasal cannula in bronchiolitis. Health Economics Review, 2021, 11, 41.	0.8	9
20	Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma. BMC Pulmonary Medicine, 2021, 21, 397.	0.8	9
21	Costâ∈utility of asâ€needed combination lowâ€dose budesonideâ€formoterol in adolescents mild asthma. Pediatric Pulmonology, 2021, 56, 3699-3705.	1.0	8
22	Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. BMC Research Notes, 2019, 12, 584.	0.6	7
23	Una percepci \tilde{A}^3 n en m \tilde{A} ©dicos bogotanos acerca del riesgo de reacciones adversas a grupos de medicamentos de uso com \tilde{A}^e n. Biomedica, 2014, 34, .	0.3	7
24	Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 575-580.	0.7	7
25	Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. BMC Pulmonary Medicine, 2021, 21, 398.	0.8	7
26	SMART therapy in adolescent and adults patients with moderate persistent asthma: a cost-utility analysis. Journal of Asthma, 2022, 59, 2367-2374.	0.9	7
27	The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis. BMC Health Services Research, 2020, 20, 1001.	0.9	6
28	Cost-utility of azithromycin in patients with severe asthma. Journal of Asthma, 2022, 59, 2008-2015.	0.9	6
29	Actitudes, conocimientos y creencias del paciente hipertenso respecto a la medicaci \tilde{A}^3 n antihipertensiva. Biomedica, 2012, 32, .	0.3	5
30	Social and economic variables related with Paraquat self-poisoning: an ecological study. BMC Public Health, 2020, 20, 404.	1.2	5
31	Budget impact analysis of high-flow nasal cannula for infant bronchiolitis: the Colombian National Health System perspective. Current Medical Research and Opinion, 2021, 37, 1627-1632.	0.9	5
32	MioclonÃas inducidas por salbutamol. Biomedica, 2018, 38, 303-307.	0.3	4
33	Cost of Illness of Paraquat Poisoning in Colombia. Value in Health Regional Issues, 2019, 20, 110-114.	0.5	4
34	Costâ€effectiveness analysis of phenotypicâ€guided versus guidelinesâ€guided bronchodilator therapy in viral bronchiolitis. Pediatric Pulmonology, 2021, 56, 187-195.	1.0	4
35	Inappropriate antibiotic prescribing for acute bronchiolitis in Colombia: a predictive model. Journal of Pharmaceutical Policy and Practice, 2021, 14, 2.	1.1	4
36	Budget impact analysis of surfactant therapy for bronchiolitis in critically ill infants: the Colombian National Health System perspective. BMC Health Services Research, 2021, 21, 334.	0.9	4

#	Article	IF	Citations
37	Clinical Manifestations and Outcomes of Respiratory Syncytial Virus Infection in Children Less Than Two Years in Colombia. Indian Pediatrics, 2021, 58, 1091-1092.	0.2	4
38	Dupilumab in children with moderateâ€toâ€severe asthma: A cost utility analysis. Pediatric Pulmonology, 2022, 57, 2313-2319.	1.0	4
39	Clinical Manifestations and Outcomes of Respiratory Syncytial Virus Infection in Children Less Than Two Years in Colombia. Indian Pediatrics, 2021, 58, 1091-1092.	0.2	3
40	Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze. Pediatric, Allergy, Immunology, and Pulmonology, 2022, 35, 36-42.	0.3	3
41	Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis. BMC Pulmonary Medicine, 2022, 22, .	0.8	3
42	Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis. Archivos Argentinos De Pediatria, 2019, 117, e466-e472.	0.3	2
43	Disability-adjusted life years for acute bronchiolitis in infants in Colombia. Pan African Medical Journal, 2021, 39, 236.	0.3	2
44	As-Needed Use of Short-Acting Î ² 2-Agonists Alone Versus As-Needed Use of Short-Acting Î ² 2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1562-1568.	2.0	2
45	The role of high carbohydrate-rich food intake and severity of asthma exacerbation in children between 2 to 6 years aged. Journal of Asthma, 2023, 60, 412-418.	0.9	2
46	Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source. BMC Pediatrics, 2022, 22, 226.	0.7	2
47	TLR4 Gene Polymorphisms Interaction With Ascaris Infection in Severe RSV Bronchiolitis. Frontiers in Pediatrics, 2022, 10, 876882.	0.9	2
48	Comparison of three alternatives for the management of moderate asthma in children aged 6–11 years: a cost-utility analysis. Journal of Asthma, 2023, 60, 761-768.	0.9	2
49	Uso del Registro de Solicitudes de Medicamentos no Incluidos en el Listado de Medicamentos Esenciales como Nueva Fuente de Informaci \tilde{A}^3 n en los Sistemas Nacionales de Farmacovigilancia. Value in Health Regional Issues, 2013, 2, 357-360.	0.5	1
50	Risk factors for severe bronchiolitis in Colombia. Tropical Doctor, 2021, 51, 434-437.	0.2	1
51	Budget impact analysis of intravenous magnesium sulfate for treating asthma exacerbations in children. Pediatric Pulmonology, 2021, 56, 2370-2371.	1.0	1
52	The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A costâ€effectiveness analysis. Pediatric Pulmonology, 2021, 56, 3706-3713.	1.0	1
53	Budget Impact Analysis of Hypertonic Saline Inhalations for Infant Bronchiolitis: The Colombian National Health System Perspective. Value in Health Regional Issues, 2022, 28, 14-18.	0.5	1
54	Bronchopulmonary dysplasia: Incidence and severity in premature infants born at high altitude. Pediatric Pulmonology, 2021, , .	1.0	1

#	Article	IF	CITATIONS
55	Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. Experimental and Clinical Transplantation, 2015, 13, 441-8.	0.2	1
56	Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis. Journal of Asthma, 2022, , 1-8.	0.9	1
57	Vitamin A supplementation for the prevention of chronic lung disease in premature infants: A costâ€utility analysis. Pediatric Pulmonology, 2022, 57, 2511-2517.	1.0	1
58	Occult bacteraemia in children with fever without focus though previously vaccinated against pneumococcus. Tropical Doctor, 0, , 004947552210929.	0.2	0
59	Importance of respiratory syncytial virus as a predictor of hospital length of stay in bronchiolitis. F1000Research, 0, 10, 110.	0.8	0